Retatrutide Dosage Chart & Schedule
An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.
Investigational triple agonist, not approved for any use. Phase-2 trials administered it once weekly with a slow titration reported up to about 12 mg weekly.
Figures describe how Retatrutide is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Once weekly
- Weekly total
- 1-2 mg
- Cycle
- ~4 weeks, then titrate
Trials began at a low weekly dose and escalated gradually; framed as investigational, not a recommendation.
- Frequency
- Once weekly
- Weekly total
- 4 mg
- Cycle
- Hold ~4 weeks per step
Mid-titration step within the studied range as exposure is increased monthly.
- Frequency
- Once weekly
- Weekly total
- 8-12 mg
- Cycle
- Trial duration
Highest weekly doses studied in phase-2 trials; 12 mg was the top reported step, not an approved target.
Triple agonist, investigational
- Targets the GIP, GLP-1, and glucagon receptors simultaneously; the added glucagon activity is associated with raised energy expenditure.
- Phase-2 obesity trials used once-weekly titration up to about 12 mg and reported among the largest weight reductions seen for an incretin-class agent.
- Not approved for human use; all dosing is from clinical trials.
Ready to run this protocol?
Dosing is only as good as the vial. Retatrutide is third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
Weekly schedule
A typical week on the maintenance protocol (Once weekly).
Dosing day Off
Retatrutide reconstitution
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
From vial to injection in 6 steps
Wipe both vial tops
Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.
Draw the water
Pull the planned amount of bacteriostatic water (2 mL) into the syringe.
Add it slowly
Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.
Let it dissolve
Wait until the solution is fully clear, then refrigerate the vial.
Draw your dose
Pull the calculated units on a U-100 insulin syringe (~40 units for 2 mg).
Store between uses
Keep the reconstituted vial refrigerated and use within its stable window.
Handling & storage
- A 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL, so 2 mg draws to about 40 units on a U-100 syringe.
- Higher titration steps exceed 1 mL at 5 mg/mL; a more concentrated mix (less water) keeps a single injection under 1 mL.
- Refrigerate reconstituted solution; protect lyophilized powder from light and heat.
Retatrutide dosing FAQ
Is retatrutide approved?
No. It is investigational, and every dose here reflects clinical-trial protocols rather than an approved regimen.
How was it titrated in trials?
Trials started at a low weekly dose and escalated gradually (roughly monthly) up to about 12 mg weekly to manage gastrointestinal tolerability.
How does it differ from semaglutide and tirzepatide?
It adds glucagon-receptor agonism to the GIP and GLP-1 activity, engaging three metabolic pathways instead of one or two; all three are once-weekly subcutaneous compounds.
Sources
Categories: GLP-1 & Metabolic · Status: Investigational. This page is educational and for laboratory research use only; it is not medical advice.